IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In respondication of: Me

Meade et al.

Serial No.:

09/012,904

Group No.:

1636

Filed:

01/23/1998

Examiner:

Celine X. Qian

For:

Transgenic Production of Antibodies in Milk

Attorney Docket Number:

GTC-1 D3

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AFTER THE FIRST OFFICE ACTION ON THE MERITS BUT BEFORE MAILING OF EITHER A FINAL ACTION OR A NOTICE OF ALLOWANCE (37 CFR 1.97(c))

1. Authority

Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject mater claimed in the above-identified application. The Applicant also encloses copies of the Englishlanguage cited documents.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist. Applicant does note that its representation before the USPTO has recently changed.

In submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that any document cited in this Supplemental Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § \$ 102 and 103.

2. Time of transmittal of accompanying Supplemental Information Disclosure Statement

The Supplemental Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this application *and after* the mailing date of the first Office action on the merits, but *before* the mailing date of either:

- (1) a final action under § 1.113, or
- (2) a notice of allowance under § 1.311, whichever occurs first.

33/10/2004 CNGUYEN 00000146 502092

180.00 DA

CERTIFICATE OF MAILING BY EXPRESS MAIL

I hereby certify that under 37 CFR §1.10 that this correspondence is being deposited on March 5, 3004 with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

3. Amount of Fee

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Supplemental Information Disclosure Statement under § 1.97(c).

Fee due \$ 180.00

4. Authority to charge Deposit Account

Please charge this \$180.00 and any other necessary fees which may be required during the entire pendency of this application to Deposit Account No. 502092. A duplicate of this transmittal is enclosed for this purpose.

5. Foreign Search Reports

A copy of the PCT International Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the

information in the attorney's file.

Dated:

By:

Byron V. Olsen, Reg. No. 42,960

Attorney for Applicant

GTC Biotherapeutics, Inc.

175 Crossing Blvd., Suite 410

Framingham, MA 01702

Tel. #(508) 370-5150 Fax #(508) 370-3797

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| Complete if Known | | | |
|------------------------|----------------|--|--|
| Application Number | 09/012,904 | | |
| Filing Date | 01/23/1998 | | |
| First Named Inventor | Harry M. Meade | | |
| Art Unit | 1636 | | |
| Examiner Name | Celine X. Qian | | |
| Attorney Docket Number | GTC-1 D3 | | |

| Sheet | 1 | 1 of 2 | | Attomey Docket Number GTC-1 D3 | | |
|--------------------|--------------|---|--------------------------------|---|-----------------------------------|--|
| | | , | U. S. PATENT | DOCUMENTS | | |
| Examiner Initials* | Cite No.1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee of Applicant of Cited Docu | ment Relevant Passages or Relevan | |
| | ļ | Number-Kind Code ^{2 (# known)} US- | | | Figures Appear | |
| | | | | | | |
| | | US- | | , | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | · | | | |
| - | | US- | | | | |
| | | US- | | | | |
| | | US- | | - | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | 2 | |
| | İ | US- | | | | |
| | | US- | | | | |
| | + | US- | | | | |

| | | | IGN PATENT DOCU | IMENTS | | |
|--|--------------|--|------------------|--|---|----------------|
| | Cite No.1 | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T _e |
| | | Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>) | MM-DD-YYYY | | | |
| | | EP 0 279 582 A | 08-24-1988 | Baylor College | | |
| | | WO 91 08216 A | 06-13-1991 | GenPharm | | |
| | | | | | | L |
| | | | 2 | | | |
| | | | | | | L |
| | | | | · | - | |

| | | | _ |
|-----------|------------|---|---|
| Examiner | Date | _ | |
| Signature | Considered | | |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, P.O. Box 1450, Alexandria, VA 22313,1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known **Application Number** 09/012,904 **Filing Date** INFORMATION DISCLOSURE 01/23/1998 STATEMENT BY APPLICANT **First Named Inventor** Harry M. Meade Art Unit 1636 (Use as many sheets as necessary) **Examiner Name** Celine X. Qian Attorney Docket Number Sheet GTC-1 D3 12

| | | NON PATENT LITERATURE DOCUMENTS | |
|--|--|---|--|
| Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number(s), publisher, city and/or country where published. | | | |
| | | YOM et al., Genetic Engineering of Milk Composition: Modification of Milk Components in Lactating Transgenic Animals, Am J Clin Nutr, 1993: 58, pgs. 299S-306S. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | - | |
| | | | |
| | | | |
| | | | |
| Examiner Signature | | Date Considered | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: